0001063537 RiceBran Technologies false --12-31 Q3 2023 20,000,000 20,000,000 3,000 3,000 150 150 150 150 150 150 0 0 15,000,000 15,000,000 6,608,376 6,608,376 6,309,509 6,309,509 3,475 1,451 40 9.6 2 7.0 7.0 15.3 10.3 September 30, 2024 September 30, 2024 2.5 2.5 450 46 46 June 30, 2025 June 30, 2025 3.6 3.6 144 144 August 31, 2025 August 31, 2025 14.0 14.0 37 37 25.2 25.2 6 1.26 0.001 00010635372023-01-012023-09-30 xbrli:shares 00010635372023-12-13 thunderdome:item iso4217:USD 00010635372023-07-012023-09-30 00010635372022-07-012022-09-30 00010635372022-01-012022-09-30 iso4217:USDxbrli:shares 00010635372023-09-30 00010635372022-12-31 0001063537ribt:LineOfCreditWithBankMember2023-09-30 0001063537ribt:LineOfCreditWithBankMember2022-12-31 0001063537us-gaap:SeriesGPreferredStockMember2023-09-30 0001063537us-gaap:SeriesGPreferredStockMember2022-12-31 0001063537ribt:FactoringAgreementMember2023-01-012023-09-30 0001063537ribt:FactoringAgreementMember2022-01-012022-09-30 0001063537ribt:LineOfCreditWithBankMember2023-01-012023-09-30 0001063537ribt:LineOfCreditWithBankMember2022-01-012022-09-30 00010635372021-12-31 00010635372022-09-30 0001063537ribt:FunicularMemberus-gaap:SubsequentEventMember2023-12-012023-12-01 0001063537ribt:FunicularFinancingMemberus-gaap:SubsequentEventMember2023-12-01 0001063537ribt:FunicularWarrantsMemberus-gaap:SubsequentEventMember2023-12-01 xbrli:pure 0001063537ribt:OldWarrantsMemberus-gaap:SubsequentEventMember2023-12-01 0001063537ribt:OldWarrantsMemberus-gaap:SubsequentEventMember2023-12-012023-12-01 0001063537ribt:NewWarrantsMemberus-gaap:SubsequentEventMember2023-12-01 0001063537ribt:MortgageAgreementMemberus-gaap:SubsequentEventMember2023-12-012023-12-01 0001063537us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberribt:StabilizedRiceBranSRBMember2023-06-232023-06-23 0001063537us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberribt:StabilizedRiceBranSRBMember2023-06-23 0001063537us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberribt:StabilizedRiceBranSRBMember2023-06-30 0001063537us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberribt:StabilizedRiceBranSRBMember2023-01-012023-06-30 0001063537us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberribt:StabilizedRiceBranSRBMember2023-07-012023-09-30 0001063537us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberribt:StabilizedRiceBranSRBMember2022-07-012022-09-30 0001063537us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberribt:StabilizedRiceBranSRBMember2023-01-012023-09-30 0001063537us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberribt:StabilizedRiceBranSRBMember2022-01-012022-09-30 0001063537us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberribt:StabilizedRiceBranSRBMember2022-12-31 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerAMember2023-07-012023-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerBMember2023-07-012023-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerCMember2023-07-012023-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerDMember2023-07-012023-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerAMember2022-07-012022-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerBMember2022-07-012022-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerCMember2022-07-012022-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerDMember2022-07-012022-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerAMember2023-01-012023-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerBMember2023-01-012023-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerCMember2023-01-012023-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerDMember2023-01-012023-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerAMember2022-01-012022-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerBMember2022-01-012022-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerCMember2022-01-012022-09-30 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerDMember2022-01-012022-09-30 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerAMember2023-01-012023-09-30 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerBMember2023-01-012023-09-30 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerCMember2023-01-012023-09-30 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerDMember2023-01-012023-09-30 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerAMember2022-01-012022-12-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerBMember2022-01-012022-12-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerCMember2022-01-012022-12-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerDMember2022-01-012022-12-31 0001063537ribt:RiceProductsMember2023-07-012023-09-30 0001063537ribt:RiceProductsMember2022-07-012022-09-30 0001063537ribt:RiceProductsMember2023-01-012023-09-30 0001063537ribt:RiceProductsMember2022-01-012022-09-30 0001063537ribt:BarleyProductsMember2023-07-012023-09-30 0001063537ribt:BarleyProductsMember2022-07-012022-09-30 0001063537ribt:BarleyProductsMember2023-01-012023-09-30 0001063537ribt:BarleyProductsMember2022-01-012022-09-30 0001063537us-gaap:ProductAndServiceOtherMember2023-07-012023-09-30 0001063537us-gaap:ProductAndServiceOtherMember2022-07-012022-09-30 0001063537us-gaap:ProductAndServiceOtherMember2023-01-012023-09-30 0001063537us-gaap:ProductAndServiceOtherMember2022-01-012022-09-30 0001063537us-gaap:LandMember2023-09-30 0001063537us-gaap:LandMember2022-12-31 0001063537us-gaap:FurnitureAndFixturesMember2023-09-30 0001063537us-gaap:FurnitureAndFixturesMember2022-12-31 utr:Y 0001063537us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2023-09-30 0001063537us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2023-09-30 0001063537ribt:PlantMember2023-09-30 0001063537ribt:PlantMember2022-12-31 0001063537ribt:PlantMembersrt:MinimumMember2023-09-30 0001063537ribt:PlantMembersrt:MaximumMember2023-09-30 0001063537ribt:ComputerAndSoftwareMember2023-09-30 0001063537ribt:ComputerAndSoftwareMember2022-12-31 0001063537ribt:ComputerAndSoftwareMembersrt:MinimumMember2023-09-30 0001063537ribt:ComputerAndSoftwareMembersrt:MaximumMember2023-09-30 0001063537us-gaap:LeaseholdImprovementsMember2023-09-30 0001063537us-gaap:LeaseholdImprovementsMember2022-12-31 0001063537us-gaap:LeaseholdImprovementsMembersrt:MinimumMember2023-09-30 0001063537us-gaap:LeaseholdImprovementsMembersrt:MaximumMember2023-09-30 0001063537us-gaap:MachineryAndEquipmentMember2023-09-30 0001063537us-gaap:MachineryAndEquipmentMember2022-12-31 0001063537us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2023-09-30 0001063537us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2023-09-30 0001063537srt:MinimumMember2023-09-30 0001063537srt:MaximumMember2023-09-30 0001063537ribt:FinanceAgreementsForAnnualInsurancePremiumsMember2023-09-30 0001063537ribt:FactoringAgreementMemberus-gaap:LineOfCreditMember2019-10-31 0001063537ribt:FactoringAgreementMemberus-gaap:LineOfCreditMember2019-01-012019-10-31 0001063537ribt:MortgageAgreementMember2022-09-302022-09-30 0001063537ribt:MortgageAgreementMemberus-gaap:PrimeRateMember2022-09-302022-09-30 0001063537ribt:MortgageAgreementMemberus-gaap:PrimeRateMember2022-12-31 0001063537ribt:MortgageAgreementMemberus-gaap:PrimeRateMember2023-01-31 0001063537ribt:FactoringAgreementMemberus-gaap:LineOfCreditMember2023-07-012023-09-30 0001063537ribt:FactoringAgreementMemberus-gaap:LineOfCreditMember2022-07-012022-09-30 0001063537ribt:FactoringAgreementMemberus-gaap:LineOfCreditMember2023-01-012023-09-30 0001063537ribt:FactoringAgreementMemberus-gaap:LineOfCreditMember2022-01-012022-09-30 0001063537ribt:LineOfCreditWithBankMember2023-07-012023-09-30 0001063537ribt:MortgageAgreementMember2023-09-30 0001063537ribt:MortgageAgreementMember2022-12-31 0001063537ribt:MortgageAgreementMemberus-gaap:PrimeRateMember2023-01-012023-09-30 0001063537ribt:MortgageAgreementMemberus-gaap:PrimeRateMember2022-01-012022-12-31 0001063537ribt:MortgageAgreementMember2023-01-012023-09-30 0001063537ribt:MortgageAgreementMember2022-01-012022-12-31 0001063537ribt:EquipmentNotesMay2021Memberus-gaap:NotesPayableOtherPayablesMember2023-09-30 0001063537ribt:EquipmentNotesMay2021Memberus-gaap:NotesPayableOtherPayablesMember2022-12-31 0001063537ribt:EquipmentNotesMay2021Memberus-gaap:NotesPayableOtherPayablesMember2023-01-012023-09-30 0001063537ribt:EquipmentNotesMay2021Memberus-gaap:NotesPayableOtherPayablesMember2022-01-012022-12-31 0001063537ribt:EquipmentNotesJune2023Memberus-gaap:NotesPayableOtherPayablesMember2023-09-30 0001063537ribt:EquipmentNotesJune2023Memberus-gaap:NotesPayableOtherPayablesMember2022-12-31 0001063537ribt:EquipmentNotesJune2023Memberus-gaap:NotesPayableOtherPayablesMember2023-01-012023-09-30 0001063537ribt:EquipmentNotesJune2023Memberus-gaap:NotesPayableOtherPayablesMember2022-01-012022-12-31 0001063537ribt:ProgressPaymentAgreementMember2023-09-30 0001063537ribt:ProgressPaymentAgreementMember2022-12-31 0001063537ribt:MortgageAgreementAtModificationMember2023-01-31 0001063537ribt:MortgageAgreementAtModificationMember2023-01-012023-01-31 0001063537ribt:MortgageAgreementMember2023-01-31 0001063537ribt:OverAdvanceNoteMember2023-01-31 0001063537ribt:MortgageAgreementAtModificationMemberus-gaap:PrimeRateMember2023-01-312023-01-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2022-12-31 0001063537us-gaap:CommonStockMember2022-12-31 0001063537us-gaap:PreferredStockMember2022-12-31 0001063537us-gaap:RetainedEarningsMember2022-12-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-01-012023-03-31 0001063537us-gaap:CommonStockMember2023-01-012023-03-31 0001063537us-gaap:PreferredStockMember2023-01-012023-03-31 0001063537us-gaap:RetainedEarningsMember2023-01-012023-03-31 00010635372023-01-012023-03-31 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-01-012023-03-31 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:CommonStockMember2023-01-012023-03-31 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:PreferredStockMember2023-01-012023-03-31 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:RetainedEarningsMember2023-01-012023-03-31 0001063537ribt:StockUnitsIssuedSUIMember2023-01-012023-03-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-03-31 0001063537us-gaap:CommonStockMember2023-03-31 0001063537us-gaap:PreferredStockMember2023-03-31 0001063537us-gaap:RetainedEarningsMember2023-03-31 00010635372023-03-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-04-012023-06-30 0001063537us-gaap:CommonStockMember2023-04-012023-06-30 0001063537us-gaap:PreferredStockMember2023-04-012023-06-30 0001063537us-gaap:RetainedEarningsMember2023-04-012023-06-30 00010635372023-04-012023-06-30 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-04-012023-06-30 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:CommonStockMember2023-04-012023-06-30 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:PreferredStockMember2023-04-012023-06-30 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:RetainedEarningsMember2023-04-012023-06-30 0001063537ribt:StockUnitsIssuedSUIMember2023-04-012023-06-30 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-06-30 0001063537us-gaap:CommonStockMember2023-06-30 0001063537us-gaap:PreferredStockMember2023-06-30 0001063537us-gaap:RetainedEarningsMember2023-06-30 00010635372023-06-30 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-07-012023-09-30 0001063537us-gaap:CommonStockMember2023-07-012023-09-30 0001063537us-gaap:PreferredStockMember2023-07-012023-09-30 0001063537us-gaap:RetainedEarningsMember2023-07-012023-09-30 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-07-012023-09-30 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:CommonStockMember2023-07-012023-09-30 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:PreferredStockMember2023-07-012023-09-30 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:RetainedEarningsMember2023-07-012023-09-30 0001063537ribt:StockUnitsIssuedSUIMember2023-07-012023-09-30 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-09-30 0001063537us-gaap:CommonStockMember2023-09-30 0001063537us-gaap:PreferredStockMember2023-09-30 0001063537us-gaap:RetainedEarningsMember2023-09-30 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2021-12-31 0001063537us-gaap:CommonStockMember2021-12-31 0001063537us-gaap:PreferredStockMember2021-12-31 0001063537us-gaap:RetainedEarningsMember2021-12-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2022-01-012022-03-31 0001063537us-gaap:CommonStockMember2022-01-012022-03-31 0001063537us-gaap:PreferredStockMember2022-01-012022-03-31 0001063537us-gaap:RetainedEarningsMember2022-01-012022-03-31 00010635372022-01-012022-03-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2022-03-31 0001063537us-gaap:CommonStockMember2022-03-31 0001063537us-gaap:PreferredStockMember2022-03-31 0001063537us-gaap:RetainedEarningsMember2022-03-31 00010635372022-03-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2022-04-012022-06-30 0001063537us-gaap:CommonStockMember2022-04-012022-06-30 0001063537us-gaap:PreferredStockMember2022-04-012022-06-30 0001063537us-gaap:RetainedEarningsMember2022-04-012022-06-30 00010635372022-04-012022-06-30 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2022-06-30 0001063537us-gaap:CommonStockMember2022-06-30 0001063537us-gaap:PreferredStockMember2022-06-30 0001063537us-gaap:RetainedEarningsMember2022-06-30 00010635372022-06-30 0001063537us-gaap:PreferredStockMember2022-07-012022-09-30 0001063537us-gaap:CommonStockMember2022-07-012022-09-30 0001063537us-gaap:RetainedEarningsMember2022-07-012022-09-30 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2022-07-012022-09-30 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2022-09-30 0001063537us-gaap:CommonStockMember2022-09-30 0001063537us-gaap:PreferredStockMember2022-09-30 0001063537us-gaap:RetainedEarningsMember2022-09-30 0001063537us-gaap:EmployeeStockOptionMemberribt:The2014EquityIncentivePlanMember2023-07-012023-09-30 0001063537us-gaap:EmployeeStockOptionMemberribt:The2014EquityIncentivePlanMember2022-07-012022-09-30 0001063537us-gaap:EmployeeStockOptionMemberribt:The2014EquityIncentivePlanMember2023-01-012023-09-30 0001063537us-gaap:EmployeeStockOptionMemberribt:The2014EquityIncentivePlanMember2022-01-012022-09-30 0001063537us-gaap:RestrictedStockUnitsRSUMemberribt:The2014EquityIncentivePlanMember2023-07-012023-09-30 0001063537us-gaap:RestrictedStockUnitsRSUMemberribt:The2014EquityIncentivePlanMember2022-07-012022-09-30 0001063537us-gaap:RestrictedStockUnitsRSUMemberribt:The2014EquityIncentivePlanMember2023-01-012023-09-30 0001063537us-gaap:RestrictedStockUnitsRSUMemberribt:The2014EquityIncentivePlanMember2022-01-012022-09-30 0001063537ribt:The2014EquityIncentivePlanMember2023-07-012023-09-30 0001063537ribt:The2014EquityIncentivePlanMember2022-07-012022-09-30 0001063537ribt:The2014EquityIncentivePlanMember2023-01-012023-09-30 0001063537ribt:The2014EquityIncentivePlanMember2022-01-012022-09-30 0001063537us-gaap:RestrictedStockUnitsRSUMember2022-12-31 0001063537us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-31 0001063537ribt:StockUnitsIssuedSUIMember2022-12-31 0001063537ribt:StockUnitsIssuedSUIMember2022-01-012022-12-31 0001063537us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-31 0001063537us-gaap:RestrictedStockUnitsRSUMember2023-03-31 0001063537ribt:StockUnitsIssuedSUIMember2023-03-31 0001063537us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-30 0001063537us-gaap:RestrictedStockUnitsRSUMember2023-06-30 0001063537ribt:StockUnitsIssuedSUIMember2023-06-30 0001063537us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-30 0001063537us-gaap:RestrictedStockUnitsRSUMember2023-09-30 0001063537ribt:StockUnitsIssuedSUIMember2023-09-30 0001063537ribt:DeferredRestrictedStockUnitsRsusMember2023-09-30 00010635372023-07-012023-07-31 0001063537us-gaap:SeriesHPreferredStockMember2023-07-31 0001063537us-gaap:SeriesHPreferredStockMember2023-07-012023-07-31 00010635372023-07-31 0001063537ribt:PreferredSharePurchaseRightMemberus-gaap:SeriesHPreferredStockMember2023-07-31 0001063537ribt:PreferredSharePurchaseRightMember2023-07-31 0001063537us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-30 0001063537us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-30 0001063537us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-30 0001063537us-gaap:FairValueMeasurementsRecurringMember2023-09-30 0001063537us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0001063537us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0001063537us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0001063537us-gaap:FairValueMeasurementsRecurringMember2022-12-31 0001063537ribt:WarrantAMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-09-13 0001063537ribt:WarrantAMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-09-30 0001063537ribt:WarrantAMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-09-132021-09-13 0001063537us-gaap:MeasurementInputExercisePriceMember2023-09-30 0001063537us-gaap:MeasurementInputExercisePriceMember2022-12-31 0001063537us-gaap:MeasurementInputPriceVolatilityMember2023-09-30 0001063537us-gaap:MeasurementInputPriceVolatilityMember2022-12-31 0001063537us-gaap:MeasurementInputRiskFreeInterestRateMember2023-09-30 0001063537us-gaap:MeasurementInputRiskFreeInterestRateMember2022-12-31 0001063537us-gaap:MeasurementInputExpectedTermMember2023-09-30 0001063537us-gaap:MeasurementInputExpectedTermMember2022-12-31 0001063537us-gaap:MeasurementInputExpectedDividendRateMember2023-09-30 0001063537us-gaap:MeasurementInputExpectedDividendRateMember2022-12-31 00010635372023-01-312023-01-31 0001063537us-gaap:OtherIncomeMember2023-01-012023-09-30
 

 

Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


FORM 10-Q

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2023

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number 001-36245

RiceBran Technologies

(Exact Name of Registrant as Specified in its Charter)

 

California

(State or other jurisdiction of

incorporation or organization)

87-0673375

(I.R.S. Employer Identification No.)

25420 Kuykendahl Rd., Suite B300

Tomball, TX

 (Address of Principal Executive Offices) 

77375

(Zip Code)

(281) 675-2421

(Registrant’s telephone number, including area code)

None

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading symbol

 

Name of each exchange on which registered

Common Stock, no par value per share

 

RIBT

 

OTC Markets (Pinks)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or an emerging company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐Accelerated filer ☐Non-accelerated filerSmaller reporting company
   Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule l2b-2 of the Exchange Act). Yes  No ☒

 

As of December 13, 2023, there were 9,512,741 shares of common stock outstanding.

 

 

  

 
 

 

RiceBran Technologies

Index

Form 10-Q

 

PART I. FINANCIAL INFORMATION Page

 

Item 1.

Financial Statements (Unaudited)

3

 

 

Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2023 and 2022

3
   

Condensed Consolidated Balance Sheets as of September 30, 2023, and December 31, 2022

4
   

Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022

5
   

Notes to Unaudited Condensed Consolidated Financial Statements

6

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

18

 

Item 4.

Controls and Procedures

18

PART II. OTHER INFORMATION  

 

Item 1.

Legal Proceedings

19

 

Item 1A.

Risk Factors

19

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

19

 

Item 3.

Defaults Upon Senior Securities

20

 

Item 4.

Mine Safety Disclosures

20

 

Item 5.

Other Information

20

 

Item 6.

Exhibits

20

Signatures 22

 

Cautionary Note about Forward-Looking Statements

 

This quarterly report on Form 10-Q contains “forward-looking statements” concerning our operations, economic performance and financial condition. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue, liquidity or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services, products or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words. The forward-looking statements contained herein reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Actual results may differ materially from those projected in such forward-looking statements due to a number of factors, risks and uncertainties, including the factors that may affect future results set forth in this Quarterly Report on Form 10-Q, in our Annual Report on Form 10-K for the year ended December 31, 2022 and in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023. Forward-looking statements speak only as of the date on which they are made, and we disclaim any obligation to update any forward-looking statements as a result of developments occurring after the date of this quarterly report.

 

Unless the context requires otherwise, references to “we,” “us,” “our” and “the Company” refer to RiceBran Technologies and its consolidated subsidiaries.

 

2

  

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

RiceBran Technologies

Condensed Consolidated Statements of Operations

(Unaudited) (in thousands, except share and per share amounts)

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2023

  

2022

  

2023

  

2022

 
                 

Revenues

 $4,857  $6,637  $16,970  $19,209 

Cost of goods sold

  5,337   7,199   17,484   20,192 

Gross loss

  (480)  (562)  (514)  (983)

Selling, general and administrative expenses

  1,250   1,436   4,352   4,021 

Loss from continuing operations before other income (expense)

  (1,730)  (1,998)  (4,866)  (5,004)

Interest income

  (1)  7   26   9 

Interest expense

  (123)  (125)  (476)  (343)

Change in fair value of derivative warrant liability

  53   612   14   24 

Other expense

  106   (39)  (3)  (111)

Other income

  (87)  -   178   5 

Loss from continuing operations before income taxes

  (1,782)  (1,543)  (5,121)  (5,420)

Income tax expense

  -   (8)  (11)  (20)

Loss from continuing operations

  (1,782)  (1,551)  (5,132)  (5,440)

Loss from discontinued operations

  -   (491)  (9,009)  (739)

Net loss

 $(1,782) $(2,042) $(14,141) $(6,179)
                 

Basic and diluted loss per common share:

                

Continuing operations

 $(0.26) $(0.29) $(0.77) $(1.03)

Discontinued operations

  -   (0.09)  (1.34)  (0.14)
  $(0.26) $(0.38) $(2.11) $(1.17)
                 

Weighted average number of shares outstanding:

                

Basic

  6,806,353   5,332,308   6,699,963   5,290,780 

Diluted

  6,806,353   5,332,308   6,699,963   5,290,780 

 

See Notes to Unaudited Condensed Consolidated Financial Statements

 

3

 

 

RiceBran Technologies

Condensed Consolidated Balance Sheets

(Unaudited) (in thousands, except share amounts)

 

  

September 30,

  

December 31,

 
  

2023

  

2022

 
ASSETS        

Current assets:

        

Cash and cash equivalents

 $466  $3,941 

Accounts receivable, net of allowance for credit losses of $49 and $27

  2,620   3,703 

Inventories

  514   465 

Other current assets

  515   735 

Current assets held for sale

  -   2,224 

Total current assets

  4,115   11,068 

Property and equipment, net

  5,937   6,020 

Operating lease right-of-use assets

  -   77 

Intangible assets

  295   380 

Long-term assets held for sale

  -   9,888 

Total assets

 $10,347  $27,433 
         

LIABILITIES AND SHAREHOLDERS' EQUITY

        

Current liabilities:

        

Accounts payable

 $1,414  $1,232 

Commodities payable

  2,538   1,546 

Accrued salary, wages and benefits

  438   489 

Accrued legal

  1,545   595 

Accrued expenses

  590   500 

Operating lease liabilities, current portion

  -   107 

Due under bank line of credit

  -   1,832 

Due under factoring agreement

  1,910   3,150 

Due under insurance premium finance agreements

  195   185 

Finance lease liabilities, current portion

  136   113 

Long-term debt, current portion

  1,273   988 

Current liabilities held for sale

  -   540 

Total current liabilities

  10,039   11,277 

Finance lease liabilities, less current portion

  434   320 

Long-term debt, less current portion

  603   836 

Derivative warrant liability

  55   69 

Long-term liabilities held for sale

  -   2,022 

Total liabilities

  11,131   14,524 

Commitments and contingencies

          

Shareholders' equity (deficit):

        

Preferred stock, 20,000,000 shares authorized: Series G, convertible, 3,000 shares authorized, stated value $150, 150 shares, issued and outstanding

  75   75 

Common stock, no par value, 15,000,000 shares authorized, 6,608,376 shares and 6,309,509 shares, issued and outstanding

  328,999   328,551 

Accumulated deficit

  (329,858)  (315,717)

Total shareholders' equity (deficit)

  (784)  12,909 

Total liabilities and shareholders' equity

 $10,347  $27,433 

 

See Notes to Unaudited Condensed Consolidated Financial Statements

 

4

 

 

RiceBran Technologies

Condensed Consolidated Statements of Cash Flows

(Unaudited) (in thousands)

 

  

Nine Months Ended September 30,

 
  

2023

  

2022

 

Cash flow from operating activities:

        
Net loss  (14,141)  (6,179)

Loss from discontinued operations

  (9,009)  (739)

Loss from continuing operations

  (5,132)  (5,440)

Adjustments to reconcile net loss to net cash used in operating activities of continuing operations

        

Depreciation

  694   671 

Amortization

  85   116 

Stock and share-based compensation

  448   817 

Change in fair value of derivative warrant liability

  (14)  (24)
Other  -   10 

Changes in operating assets and liabilities:

        

Accounts receivable

  1,083   (977)

Inventories

  (49)  106 

Accounts payable and accrued liabilities

  1,173   822 

Commodities payable

  

993

   258 
                      Assets held for sale  -   (827)

Other

  (63)  (691)

Net cash used in operating activities of continuing operations

  (782)  (4,652)

Net cash provided by (used in) operating activities of discontinued operations

  (211)  880 

Net cash used in operating activities

  (993)  (3,772)

Cash flows from investing activities:

        

Purchases of property and equipment

  (611)  (494)

Net cash used in investing activities of continuing operations

  (611)  (494)

Net cash provided by (used in) investing activities of discontinued operations

  1,679   (180)

Net cash provided by (used in) investing activities

  1,068   (674)

Cash flows from financing activities:

        

Advances on factoring agreement

  21,447   28,936 

Payments on factoring agreement

  (22,687)  (27,389)

Advances on bank line of credit

  37   1,846 

Payments on bank line of credit

  (1,869)  - 

Advances on insurance premium finance agreements

  263   794 

Payments on insurance premium finance agreements

  (253)  (493)

Capitalized loan costs

  (6)  - 
       Advances on debt and finance lease agreements  -   377 

Payments of debt and finance lease liabilities

  (22)  (967)

Net cash provided by (used in) financing activities of continuing operations

  (3,090)  3,104 

Net cash used in financing activities of discontinued operations

  (460)  (109)

Net cash provided by (used in) financing activities

  (3,550)  2,995 

Net change in cash and cash equivalents

 $(3,475) $(1,451) 
         

Cash and cash equivalents, beginning of period

 $3,941  $5,825 

Net change in cash and cash equivalents

   3,475   1,451 
Cash and cash equivalents, end of period $466  $4,374 

 

See Notes to Unaudited Condensed Consolidated Financial Statements

 

5

 

 

NOTE 1. BASIS OF PRESENTATION

 

The accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements. The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented.

 

These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2022, which included all disclosures required by generally accepted accounting principles.

 

The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business. 

 

Certain reclassifications have been made to amounts reported for the prior year to achieve consistent presentation with the current year. Such reclassifications had no impact on previously reported net loss or shareholders’ equity.

  

 

NOTE 2. LIQUIDITY AND MANAGEMENT’S PLANS

 

The Company has incurred losses and generated negative cash flows from operations since its inception. As of September 30, 2023, the Company had an accumulated deficit of $329.9 million and cash and cash equivalents of $0.5 million.

 

Our history of operating losses and negative operating cash flows from continuing operations raised substantial doubt about our ability to continue as a going concern before consideration of management’s plans, however after consideration of management’s recently completed refinancing, we believe substantial doubt about our ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued has been alleviated. The factors that alleviated the substantial doubt are summarized below:

 

On December 1, 2023, an entity owned by Cable Car Capital LLC, Funicular Funds, LP (Funicular), purchased 0.4 million of shares of common stock of the Company and lent the Company $4.0 million, less an original issue discount of $0.4 million.

 

Related to this financing, Funicular was also granted warrants to purchase up to 5.0 million shares of common stock of the Company.  If Funicular exercised all its warrants, it would own 49.8% of the Company.  The Company also exchanged existing warrants with other investors to purchase an aggregate 2.2 million shares of common stock of the Company for an aggregate of approximately 0.6 million shares of common stock of the Company and new warrants to purchase 1.2 million shares of common stock of the Company. 

 

With the proceeds of this financing, the Company repaid its $1.5 million mortgage note (see Note 9) and will use the remaining balance to fund its current and future general working capital and operating, investing and financing cash flow needs.

 

The Company also believes additional cash can be secured through other debt or structured equity financing, if necessary. However, there can be no assurance that equity or debt financing will be available to the Company should it need it or, if available, that the terms will be satisfactory to the Company and not dilutive to existing shareholders. The Company’s failure to raise capital as and when needed could have significant negative consequences for its business, financial condition, and results of consolidated operations.

 

 

NOTE 3. DISCONTINUED OPERATIONS

 

We continuously assess the composition of our portfolio to ensure it is aligned with our strategic objectives and positioned to maximize return to our shareholders. On June 23, 2023, we completed the sale of our assets related to the SRB Business for $1.8 million in cash and the assumption of $1.7 million of real estate operating leases and other liabilities. The sale agreement contained customary representations, warranties and covenants.

 

The proceeds, net of expenses, of $1.4 million, and the net carrying value of the SRB Business assets and liabilities assumed as of the date of sale at $10.0 million resulted in our recognition of a loss on sale of $8.6 million. The estimated loss on sale includes no provision for income taxes as it is anticipated the tax benefit for the expected tax loss on disposition will not be realized based on our current U.S. valuation allowance position.

 

In consideration of the Lender’s (as defined below) consent to the sale and release of securities interests and liens on SRB Business assets, we paid a portion of the amount outstanding on our mortgage promissory note, not exclusively related to the SRB Business, from proceeds of the sale. In addition, we paid liabilities for accumulated paid time off to the employees of the SRB Business. The following table summarizes the initial distribution of proceeds (in thousands).

 

Purchase price

 $1,800 

Estimated expenses, accrued as of June 30, 2023

  (375)

Net proceeds

 $1,425 
     

Repayment of mortgage promissory note

 $450 

Payment of paid time off liabilities

  215 
  $665 

 

6

 

The following table summarizes the estimated carrying amounts of the SRB Business as of June 23, 2023, the date of sale (in thousands).

 

Inventories

 $2,252 

Other current assets

  185 

Property and equipment

  7,710 
Operating lease right of use assets  1,566 

Total assets

  11,713 

Accrued expenses

  9 
Operating lease liabilities  1,668 
Finance lease liabilities  12 
Long-term debt  14 

Total liabilities

  1,703 
Net assets sold $10,010 

 

The buyer of the SRB Business did not acquire accounts receivable generated by the operation of the SRB Business assets and generally did not assume any accounts payable or accrued expenses related to the operation of the SRB Business through the June 23, 2023, date of sale. We continue to manage collections of those accounts receivable and payments of those liabilities.

 

We determined that the disposal met the criteria for presentation as discontinued operations in the second quarter of 2023. Accordingly, SRB Business results are presented as discontinued operations in our consolidated statements of operations and are excluded from continuing operations for all periods presented. In addition, the SRB Business assets and liabilities are classified as held for sale in our consolidated balance sheets for December 31, 2022. The operations of the SRB Business are included in our results through the June 23, 2023, date of sale. The following two tables represent activity up to the date of sale.

 

The following table summarizes the major line items included in loss from discontinued operations related to the SRB Business and divestiture (in thousands).

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2023

  

2022

  

2023

  

2022

 

Revenues

 $-   3,615  $6,857  $11,792 

Cost of goods sold

  -   (3,750)  (6,796)  (11,334)

Selling, general and administrative expenses

  -   (329)  (457)  (1,144)

Interest expense

  -   (27)  (28)  (53)

Loss from operations of discontinued operations

  -   (491)  (424)  (739)

Loss on sale

  -   -   (8,585)  - 

Loss from discontinued operations

 $-  $(491) $(9,009) $(739)
                 

Depreciation included in cost of goods sold

 $-  $315  $646  $921 

Capital expenditures

 $-  $433  $111  $722 

 

The following table summarizes the major line items included in cash flows from discontinued operations related to the SRB Business and divestiture (in thousands).

 

  

Nine Months Ended

September 30,

 
  

2023

  

2022

 
         

Net cash provided by (used in) operating activities

 $(211) $880 

Net cash provided by (used in) investing activities

  1,679   (180)

Net cash used in financing activities

  (460)  (109)

Net cash provided to continuing operations

 $(4,483) $(2,042)

 

In the nine months ended September 2023, net cash provided by investing activities in the table above is presented in our consolidated statements of cash flows in net cash provided by investing activities of discontinued operations and includes the $1.4 million net proceeds from the sale of the SRB Business. In the nine months ended September 2023, net cash used in financing activities in the table above is presented in our consolidated statements of cash flows used in financing activities of discontinued operations and includes the $0.5 million repayment of our mortgage promissory note from the initial proceeds from the sale.

 

7

 

The following table summarizes the carrying amounts of major classes of SRB Business assets and liabilities classified as held for sale as of December 31, 2022 (in thousands).

 

Inventories

 $1,913 

Other current assets

  311 

Property and equipment

  8,187 

Operating lease right of use assets

  1,701 

Total assets held for sale

 $12,112 

Accrued expenses, including paid time off liabilities of employees of the SRB business

  236 

Operating lease liabilities

  1,841 

Finance lease liabilities

  17 

Long-term debt, including $450 of mortgage promissory note, not exclusively related to the SRB Business

  468 

Total liabilities held for sale

 $2,562 

  

 

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Recent accounting standards not yet adopted

 

There are no accounting standards not yet adopted that have resulted, or are expected to result in a significant change in practice or have a significant financial impact on our financial position, results of operations or cash flows.

 

Recently adopted accounting standards.

 

In June 2016, the Financial Accounting Standards Board issued guidance ASU No. 2016-13 Financial InstrumentsCredit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which changes the accounting for credit losses for certain instruments, including trade receivables, from an incurred loss method to a current expected loss method. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts. We adopted the guidance, and subsequent guidance related to the topic, effective January 1, 2023. Adoption of the standard had no significant impact on our results of operations, financial position, or cash flows as of January 1, 2023. Our provision for doubtful accounts, recoveries of doubtful accounts and accounts receivable charge-offs were immaterial in all periods presented.

  

 

NOTE 5. ACCOUNTS RECEIVABLE AND REVENUES

 

Our accounts receivable potentially subject us to significant concentrations of credit risk. Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percentage of consolidated totals.

 

  

Customer

 
  

A

  

B

  

C

  

D

 

% of revenues, three months ended September 30, 2023

  26%  20%  12%  4%

% of revenues, three months ended September 30, 2022

  15%  5%  11%  -%
                 

% of revenues, nine months ended September 30, 2023

  28%  12%  10%  3%

% of revenues, nine months ended September 30, 2022

  13%  8%  5%  2%
                 

% of accounts receivable, as of September 30, 2023

  1%  39%  16%  10%

% of accounts receivable, as of December 31, 2022

  12%  19%  -%  -%

 

8

 

The following table presents disaggregated revenues (in thousands).

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2023

  

2022

  

2023

  

2022

 
                 

Rice products

 $3,439  $4,497  $11,530  $11,672 

Barley products

  1,192   1,481   4,466   5,411 

Other

  226   659   974   2,126 

Revenues

 $4,857  $6,637  $16,970  $19,209 

  

 

NOTE 6. INVENTORIES

 

The following table details the components of inventories (in thousands).

 

  

September 30,

  

December 31,

 
  

2023

  

2022

 

Finished goods

 $270  $228 

Raw materials

  225   212 

Packaging

  19   25 

Inventories

 $514  $465 

  

 

NOTE 7. PROPERTY AND EQUIPMENT

 

The following table details the components of property and equipment (amounts in thousands).

 

  

September 30,

  

December 31,

 Estimated Useful Lives
  

2023

  

2022

 

(in years)

Land

 $493  $493    

Furniture and fixtures

  -   71 

7

-10

Plant

  3,444   3,440 

20

-40 or life of lease

Computer and software

  27   382 

3

-5

Leasehold improvements

  -   152 

5

-6

Machinery and equipment

  6,436   5,758 

5

-15

Property and equipment, cost

  10,310   10,296    

Less accumulated depreciation

  4,373   4,276    

Property and equipment, net

 $5,937  $6,020    

 

 

9

  
 

NOTE 8. LEASES

 

The components of lease expense and cash flows from leases (in thousands) follow.

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2023

  

2022

  

2023

  

2022

 

Finance lease cost:

                

Amortization of right-of-use assets, included in cost of goods sold

 $36  $20  $85  $59 

Interest on lease liabilities

  14   6   41   11 

Operating lease cost, included in selling, general and administrative expenses:

                

Fixed leases cost

  26   129   80   387 

Variable lease cost

  20   39   61   125 

Short-term lease cost

  20   41   96   62 

Total lease cost

 $116  $235  $363  $644 
                 

Cash paid for amounts included in the measurement of lease liabilities:

                

Operating cash flows from finance leases

 $14  $6  $41  $11 

Operating cash flows from operating leases

 $26  $129  $80  $387 

Financing cash flows from finance leases

 $35  $22  $113  $68 

 

As of September 30, 2023, variable lease payments do not depend on a rate or index. As of September 30, 2023, property and equipment, net, includes $0.7 million of finance lease right-of-use-assets, with an original cost of $0.9 million. As of December 31, 2022, property and equipment, net, includes $0.8 million of finance lease right-of-use-assets, with an original cost of $0.9 million. During the nine months ended September 30, 2023, we financed the purchase of $0.2 million of property and equipment in noncash finance lease transactions. During the three and nine months ended September 30, 2022, we financed the purchase of $0.1 million and $0.3 million of property and equipment in noncash finance lease transactions.

 

As of September 30, 2023, we do not believe it is certain that we will exercise any renewal options. The remaining terms of our leases and the discount rates used in the calculation of our lease liabilities as of September 30, 2023, follows.

 

  

Operating

Leases

  

Finance

Leases

Remaining leases terms (in years)

  -   0.4 -4.3

Weighted average remaining lease terms (in years)

  -   3.9

Discount rates

  -   2.8%-11.6%

Weighted average discount rate

  -   9.6%

 

Maturities of lease liabilities as of September 30, 2023, follow (in thousands).

 

  

Operating

  

Finance

 
  

Leases

  

Leases

 

2023

  -  $57 

2024

  -   177 

2025

  -   167 

2026

  -   165 

2027

  -   126 

Thereafter

  -   4 

Total lease payments

  -   696 

Amounts representing interest

     (126)

Present value of lease obligations

 $-  $570 

  

 

NOTE 9. DEBT

 

We finance certain amounts owed for annual insurance premiums under financing agreements. As of September 30, 2023, amounts due under insurance premium financing agreements are due in monthly installments of principal and interest through March 2024, at an average annual interest rate of 7.5%.

 

10

 

We borrow under a factoring agreement with a lender (the Lender), which provides a $7.0 million credit facility. We may only borrow to the extent we have qualifying accounts receivable to use as collateral as defined in the agreement. The facility had an initial two-year term and automatically renews for successive annual periods until delivery of a proper termination notice. The facility term automatically extended to October 2024. We incur recurring fees under the agreement, including a funding fee of 0.5% above the prime rate, in no event to be less than 5.5%, on any advances, and a service fee on average net funds borrowed. The Lender has a security interest in our assets and the right to demand repayment of the advances at any time.

 

The Lender also advanced us $0.9 million effective September 30, 2022 (the Over-advance), pending restructuring of our mortgage promissory note with the Lender. The Over-advance accrued interest at an annual rate which was the greater of 7.0% above the Lender’s prime rate (14.5% at December 31, 2022) and 10.3% until it was repaid in January 2023. As of December 31, 2022, the Over-advance was classified as long-term debt in our consolidated balance sheet as it was refinanced on a long-term basis in January 2023, as discussed below.

 

Additional information related to our factoring obligation (exclusive of the Over-advance) follows (in thousands).

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2023

  

2022

  

2023

  

2022

 

Average borrowings outstanding

 $1,293  $3,150  $2,355  $3,036 

Interest paid on borrowings

  34   51   168   142 

Fees paid on borrowings

  26   51   131   114 

 

During the nine months ended September 30, 2023, we borrowed under a line of credit with a bank. The borrowing was secured by our cash on deposit with the bank and bore interest at prime. There were no stipulated repayment terms for the line as long as we maintained sufficient cash collateral. We repaid the amounts borrowed under the line of credit in full in April 2023. Our borrowings under the line of credit averaged $0.6 million in the nine months ended September 30, 2023. During the nine months ended September 30, 2023, the average annual interest rate on borrowings was 6.7%.

 

Long-term debt consists of the following (in thousands).

 

  

September 30,

  

December 31,

 
  

2023

  

2022

 

Mortgage promissory note - Originally dated July 2020. As subsequently modified, interest accrues at an annual rate which is the greater of 7.0% above the Lender's prime rate (15.3% at June 30, 2023) and 10.3% and payable in monthly installments through September 2024. Face amount $2.5 million. Secured by certain real property in Arkansas. December 31, 2022, excludes $450 thousand allocated to discontinued operations.

 $1,730  $1,761 

Equipment note - Dated May 2021. Original principal $46 thousand. Due in monthly installments through June 2025. Interest accrues at the effective discount rate of 3.6% per year.

 

 

17

 

   24 

Equipment note - Dated June 2023. Original principal $144 thousand. Due in monthly installments through August 2025. Interest accrues at the effective discount rate of 14.0% per year.

  129   - 

Progress payment agreement - Dated August 2022. Original principal $37 thousand. Interest was payable monthly at the rate of 25.2% per year until obligation was transferred to a finance lease in February 2023.

  -   39 

Total long-term debt, net

 $1,876  $1,824 

 

In January 2023, we entered into agreements with the Lender to effect a modification of the terms of the mortgage promissory note. This modification involved us entering into a new mortgage promissory note in the principal amount of $2.5 million. We received $0.3 million in cash, and the Lender applied the remainder of the new principal to the $1.3 million then outstanding on the prior mortgage promissory note and the $0.9 million Over-advance. Under the terms of the January 2023 note, (i) interest accrues at the same rate as the prior note, an annual rate which is the greater of 7.0% above the Lender’s prime rate and 10.3%, and (ii) principal and interest were payable in equal monthly installments through January 2025, under the January note. Prior to the January 2023 modification, principal and interest were payable in equal monthly installments through December 2023. The note is secured by a mortgage on our real property in Arkansas. The current portion of long-term debt on the consolidated balance sheet as of December 31, 2022, reflects the terms of the January 2023 modification.

 

11

 

Future principal maturities of long-term debt outstanding as of  September 30, 2023, follow (in thousands).

 

2023

$

321

2024

 

1,403

2025

 158

Principal maturities

 1,882

Debt issuance costs

 (6)

Total long-term debt, net

$1,876

  

 

NOTE 10. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS

 

A summary of equity activity for the three and nine months ended September 30, 2023 and 2022, follows (in thousands, except share amounts).

 

  

Shares

                 
  

Preferred

      

Preferred

  

Common

  

Accumulated

     
  

Series G

  

Common

  

Stock

  

Stock

  

Deficit

  

Equity

 

Balance, December 31, 2022

  150   6,309,509  $75  $328,551  $(315,717) $12,909 

Common stock awards under equity incentive plans

  -   68,693   -   300   -   300 

Stock units issued to vendor

  -   6,132   -   23   -   23 

Common stock issued to vendor

  -   600   -   1   -   1 

Net loss

  -   -   -   -   (2,028)  (2,028)

Balance, March 31, 2023

  150   6,384,934   75   328,875   (317,745)  11,205 

Common stock awards under equity incentive plans

  -   221,742   -   (12)  -   (12)

Stock units issued to vendor

  -   -   -   19   -   19 

Common stock issued to vendor

  -   600   -   1   -   1 

Net loss

  -   -   -   -   (10,331)  (10,331)

Balance, June 30, 2023

  150   6,607,276  $75  $328,883  $(328,076) $882 

Common stock awards under equity incentive plans

  -   500   -   96   -   96 

Stock units issued to vendor

  -   -   -   19   -   19 

Common stock issued to vendor

  -   600   -   1   -   1 

Net loss

  -   -   -   -   (1,782)  (1,782)

Balance, September 30, 2023

  150   6,608,376  $75  $328,999  $(329,858) $(784)

 

Balance, December 31, 2021

  150   5,158,967  $75  $326,279  $(307,859) $18,495 

Common stock awards under equity incentive plans

  -   22,475   -   241   -   241 

Common stock issued to vendor

  -   600   -   5   -   5 

Net loss

  -   -   -   -   (1,516)  (1,516)

Balance, March 31, 2022

  150   5,182,042   75   326,525   (309,375)  17,225 

Common stock awards under equity incentive plans

  -   48,388   -   146   -   146 

Common stock issued to vendor

  -   600   -   1   -   1 

Net loss

  -   -   -   -   (2,621)  (2,621)

Balance, June 30, 2022

  150   5,231,030  $75  $326,672  $(311,996) $14,751 

Common stock awards under equity incentive plans

  -   -   -   492   -   492 

Common stock issued to vendor

  -   600   -   2   -   2 

Other

  -   10,447   -   -   -   - 

Net loss

  -   -   -   -   (2,042)  (2,042)

Balance, September 30, 2022

  150   5,242,077  $75  $327,166  $(314,038) $13,203 

 

Share-based compensation by type of award, follows (in thousands).

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2023

  

2022

  

2023

  2022 

Stock options

 $69  $(54) $3  $(74)

Restricted stock units

  27   464   288   801 

Compensation expense related to common stock awards issued under equity incentive plans

 $96  $410  $291   727 

 

12

 

We have outstanding (i) restricted stock units issued under our 2014 Equity Incentive Plan (RSUs) to employees and directors and (ii) other restricted stock units held by a service provider (SUs). Each RSU and SU represents a contingent right to receive one share of common stock. Summaries of nonvested and vested restricted stock unit activity follows.

 

  

RSUs

  

SUs

 
  

Number of

Units

  

Unrecognized Compensation

(in thousands)

  

Average

Grant Date

Fair Value

per share

  

Weighted

Average

Expense

Period

(Years)

  

Number of

Units

  

Unrecognized Compensation

(in thousands)

  

Average

Grant Date

Fair Value

per share

  

Weighted

Average

Expense

Period

(Years)

 

Nonvested at December 31, 2022

  366,818  $1,024  $2.79   2.8   160,000  $201  $1.26  $3 

Granted

  76,088   70   0.93   -   6,132   5   0.75   - 

Forfeited

  (646)  (3)  5.15   0.6   -   -   -   - 

Vested with service

  (164,781)  -   -   -   (6,132)  -   -   - 

Expense

  -   (274)  -   -   -   (24)  -   - 

Nonvested at March 31, 2023

  277,479   817   2.95   2.6   160,000   182   1.14   2.5 

Granted

  60,196   60   1.00   -   -   -   -   - 

Forfeited

  (231,413)  (881)  3.81   1.3   -   -   -   - 

Vested with service

  (60,196)  -   -   -   -   -   -   - 

Vested upon involuntary termination

  (16,750)  -   -   -   -   -   -   - 

Expense reversal (expense)

  -   12   -   -   -   (19)  -   - 

Nonvested at June 30, 2023

  29,316  $8  $0.29   0.1   160,000  $163  $1.02   2.2 

Granted

  66,280   29   0.43   -   -   -   -   - 

Forfeited

  (2,000)  (8)  4.00   0.4   -   -   -   - 

Vested with service

  (92,596)  -   -   -   -   -   -   - 

Vested upon involuntary termination

  (500)  -   -   -   -   -   -   - 

Expense reversal (expense)

  -   (28)  -   -   -   (19)  -   - 

Nonvested at September 30, 2023

  500  $1  $4.12   -   160,000  $144  $0.90   2.0 

 

  

Number of

RSUs

 

Vested at December 31, 2022

  224,725 

Vested with service

  170,913 

Issued at vesting

  (74,825)

Vested at March 31, 2023

  320,813 

Vested with service

  60,196 

Vested upon involuntary termination

  16,750 

Issued at vesting

  (221,742)

Vested at June 30, 2023

  176,017 

Vested with service

  92,596 

Vested upon involuntary termination

  500 

Issued at vesting

  (500)

Vested at September 30, 2023

  268,613 

 

As of September 30, 2023, issuance of 268,613 shares of common stock subject to certain RSUs which are vested, is deferred to the date the holder is no longer providing service to our Company.

 

Under the original terms of certain RSUs outstanding during the periods presented, the nonvested portion of an RSU is vested upon the without-cause involuntary termination of the holder’s service. Under the original terms of all RSUs outstanding during the periods presented, upon voluntary or with-cause termination of the holder’s service, the nonvested portion of an RSU is forfeited and any previously recognized compensation related to the nonvested portion of an RSU is reversed because our policy is to recognize forfeitures as they occur.

 

In July 2023, we issued an option for the purchase of up to 100,000 shares of our common stock at an exercise price of $1.05 per share. The option was immediately vested and had a grant date fair value of $73 thousand.

 

Preferred Stock and Tax Benefits Preservation Plan (Rights Agreement)

 

In July 2023, in connection with the Rights Agreement described below, we designated an eighth series of preferred stock, Series H Junior Participating Preferred Stock, no par value (Series H Preferred Shares). Series H Preferred shares will be entitled, if declared, to a preferential per share quarterly dividend payment equal to the greater of (i) $1.00 per share or (ii) an amount equal to 1,000 times the dividend declared per share of our common stock. Each share of Series H Preferred Stock entitles the holder to 1,000 votes on all matters submitted to a vote of our shareholders. In the event of any merger, consolidation or other transaction in which shares of common stock are converted or exchanged, each share of Series H Preferred Stock will be entitled to receive 1,000 times the amount received per one share of our common stock.

 

13

 

In July 2023, we entered into the Rights Agreement designed to reduce the likelihood that we will experience an “ownership change” under Section 382 of the Internal Revenue Code of 1986, as amended, by (i) discouraging any person or group of persons from becoming an “Acquiring Person”, which is defined in the Rights Agreement generally as a person or group of affiliated or associated persons that, at any time after the date of the Rights Agreement, has acquired, or obtained the right to acquire, beneficial ownership of 4.95% or more of the shares of our then outstanding common stock and (ii) discouraging any existing shareholder currently beneficially holding 4.95% or more of the shares of our common stock from acquiring more shares of our common stock. In connection therewith, the Board declared a dividend of one preferred share purchase right (a Right) for each outstanding share of common stock to shareholders of record at the close of business on July 17, 2023. Each Right entitles the holder to purchase one one-thousandth of a share of our Series H Preferred Stock at a price of $6.00, subject to certain adjustments.

 

The Rights will separate and begin trading separately from our common stock generally (i) when a person or group of affiliated or associated persons has become an Acquiring Person or (ii) following the commencement, or announcement of an intention to commence, a tender offer or exchange offer the consummation of which would result in any person becoming an Acquiring Person. If issued, each Right, other than Rights beneficially owned by the Acquiring Person (which will thereupon become void) will become exercisable for common stock having a value equal to two times the exercise price of the Right. Prior to exercise, a Right does not give its holder any dividend, voting or liquidation rights. If not otherwise redeemed, exchanged or terminated, the Rights will expire in July 2026, or at such later date as may be established by the Board.

  

 

NOTE 11. INCOME TAXES

 

Our tax expense for the three and nine months ended  September 30, 2023 and 2022, differs from the tax expense computed by applying the U.S. statutory tax rate to loss from continuing operations before income taxes as no tax benefits were recorded for tax losses generated in the U.S. As of September 30, 2023, we had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards. We provided a full valuation allowance against our deferred tax assets as future realization of such assets is not more likely than not to occur.

  

 

NOTE 12. LOSS PER SHARE (EPS)

 

We calculate basic EPS under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends. Our outstanding convertible preferred stock are considered participating securities as the holders may participate in undistributed earnings with holders of common shares and are not obligated to share in our net losses.

 

We calculate diluted EPS by dividing our loss from continuing operations by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive. We calculate the dilutive effects of outstanding options, warrants and nonvested restricted stock units that vest solely on the basis of a service condition using the treasury stock method. We calculate the dilutive effects of outstanding preferred stock using the if-converted method.

 

Reconciliations of the numerators and denominators in the EPS computations for continuing operations follow.

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2023

  

2022

  

2023

  

2022

 

NUMERATOR (in thousands):

                

Basic and diluted - loss from continuing operations

 $(1,782) $(1,551) $(5,132) $(5,440)
                 

DENOMINATOR:

                

Weighted average number of shares of shares of common stock outstanding

  6,607,738   5,235,005   6,462,025   5,203,504 

Weighted average number of shares of common stock underlying vested RSUs and SUs

  198,615   97,303   237,938   87,276 

Basic and diluted EPS - weighted average number of shares outstanding

  6,806,353   5,332,308   6,699,963   5,290,780 

 

14

 

No effects of potentially dilutive securities outstanding were included in the calculation of diluted EPS for continuing operations for the three and nine months ended September 30, 2023 and 2022, because to do so would be antidilutive because of our net loss from continuing operations. Potentially dilutive securities outstanding at September 30, 2023, included our outstanding convertible preferred stock, options, warrants, nonvested RSUs and nonvested SUs.

  

 

NOTE 13. FAIR VALUE MEASUREMENTS

 

The fair value of cash and cash equivalents, accounts receivable, accounts payable, commodities payable and short-term debt approximates their carrying value due to shorter maturities. As of September 30, 2023, the fair values of our operating lease liability, long-term debt and finance lease liabilities approximated their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).

 

The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our consolidated balance sheets (in thousands):

 

  

Level 1

  

Level 2

  

Level 3

  

Total

 
                 

Total liabilities at fair value as of September 30, 2023 - Derivative warrant liability

        55  $55 

Total liabilities at fair value as of December 31, 2022 - Derivative warrant liability

 $-  $-  $69  $69 

 

The following tables summarize the changes in level 3 items measured at fair value on a recurring basis for the three and nine months ended September 30, 2023, (in thousands):

 

  

Fair Value

as of

Beginning of

Period

  

Total
Realized

and

Unrealized
Gains
(Losses)

  

Issuance of

New

Instruments

  

Net
Transfers
(Into) Out

of
Level 3

  

Fair Value,

at End of

Period

  

Change in

Unrealized

Gains

(Losses) on

Instruments

Still Held

 

Three months ended September 30, 2023

                        

Total Level 3 fair value - Derivative warrant liability

 $108  $53  $-  $-  $55  $53 

Nine months ended September 30, 2023:

                        

Total Level 3 fair value - Derivative warrant liability

 $69  $14  $-  $-  $55  $14 
                         

Three months ended September 30, 2022

                        

Total Level 3 fair value - Derivative warrant liability

 $846  $612  $-  $-  $234  $612 

Nine months ended September 30, 2022:

                        

Total Level 3 fair value - Derivative warrant liability

 $258  $24  $-  $-  $234  $24 

 

The derivative warrant liability relates to a warrant issued in September 2021 for the purchase of up to 230,769 shares of common stock (Warrant A). The current $2.72 per share exercise price of Warrant A adjusted in September 2023 to $0.57 per share, 110% of the 5-day volume weighted average price of our common stock. We classify Warrant A in our consolidated balance sheets as derivative warrant liability because the holder may elect cash settlement of this warrant in the event of a change of control. We estimated the fair value of Warrant A as of September 30, 2023, and December 31, 2022, using Black-Scholes which approximates the cash settlement the holder could elect to be paid in the event of a change of control. The changes in the estimated fair value of Warrant A are included in other income (loss) in our consolidated statements of operations. The assumptions used in valuing Warrant A follow.

 

  

September 2023

  

December 31, 2022

 

Assumed exercise price

 $0.57  $2.72 

Assumed volatility

  93.3%  92.2%

Assumed risk free interest rate

  5.4%  4.3%

Expected life of options (in years)

  3.0   3.7 

Expected dividends

  -   - 

 

 

15

  
 

NOTE 14. COMMITMENTS AND CONTINGENCIES

 

Employment Contracts and Severance Payments

 

In the normal course of business, we periodically enter into agreements which incorporate indemnification provisions. While the maximum amount to which we may be exposed under such agreements cannot be reasonably estimated, we maintain insurance coverage, which we believe will effectively mitigate our obligations under these indemnification provisions. No amounts have been recorded in our financial statements with respect to any obligations under such agreements.

 

Vesting of certain outstanding nonvested equity grants would accelerate following a change in control.

 

Legal Matters

 

From time to time, we are involved in litigation incidental to the conduct of our business. These matters may relate to employment and labor claims, patent and intellectual property claims, claims of alleged non-compliance with contract provisions and claims related to alleged violations of laws and regulations. When applicable, we record accruals for contingencies when it is probable that liability will be incurred and the amount of loss can be reasonably estimated. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations. We expense defense as incurred. Defense costs, when incurred, are included in selling, general and administrative expenses.

 

In  January 2023, we received $0.3 million in restitution payments from a former employee. The payments were ordered by a federal court in 2012. Other income in the nine months ended September 30, 2023, includes a $0.3 million gain as a result of collecting the restitution payment.

  

 

NOTE 15. SUBSEQUENT EVENTS

 

On November 8, 2023, the Nasdaq Stock Market LLC (Nasdaq) delisted the Company. The Company’s stock is now traded on the OTC Pink Market under the symbol “RIBT.”

 

16

  
 

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

 

On June 23, 2023, we completed the sale of our assets related to the production of stabilized rice bran and the processing of stabilized rice bran into stabilized rice bran derivatives at facilities located in West Sacramento, California, Mermentau, Louisiana, Lake Charles, Louisiana and Dillon, Montana (the SRB Business). The SRB Business’s results are presented as discontinued operations in our consolidated statements of operations and are excluded from continuing operations for all periods presented. See Note 3 in the Notes to Unaudited Condensed Consolidated Financial Statements for further discussion of our discontinued operations.

 

As of September 30, 2023, continuing operations included the results of operating our rice mill located in Wynne, Arkansas (Golden Ridge) and our barley and oats mill located in East Grand Forks, Minnesota (MGI).

 

Results of Continuing Operations Three Months Ended September 30, 2023 and 2022

 

Revenues of $4.8 million in the third quarter of 2023 decreased $ 1.8 million, or 26.8%, from $6.6 million in the third quarter of 2022. $1.2 million of this decrease related to Golden Ridge mainly due a lack of availably of end of the season crop leading to lower volumes.  The remaining $0.6 million revenue decrease at MGI Grain was mainly due to lower commodity prices.

 

The third quarter 2023 gross loss at both MGI Grain Incorporated (MGI Grain) and Golden Ridge Rice Mills, Inc. (Golden Ridge) decreased compared to the third quarter of 2022 by $0.1 million in total or 15.5% due to the rationalization of less profitable business due to the commodity supply changes noted above.

 

Despite increased legal and consulting costs incurred in the third quarter of 2023 as we continue to explore all our strategic alternatives, selling, general and administrative (SG&A) expenses of $1.2 million in the third quarter of 2023 still decreased $0.2 million or 12.7% from $1.4 million in the third quarter of 2022 due to continued control of other overhead expenses, mainly staff.

 

Loss from continuing operations before other income (expense) was $1.7 million in the third quarter of 2023, $0.3 million or 13.5% less than the third quarter of 2022 because of the improved gross margin and decreased SG&A expenses noted above.

 

Other expense, net, increased $0.5 million in the third quarter of 2023 compared to the third quarter of 2022 mainly due to the reduction in the gain from the change in the fair value of our derivative warrant liability.

 

As a result of the above, our third quarter 2023 loss from continuing operations was $1.8 million, or $0.26 per share, compared to $2.0 million, or $0.29 per share, in the third quarter of 2022.

 

Results of Continuing Operations Nine Months Ended September 30, 2023 and 2022

 

Primarily due to commodity input pricing changes, revenues of $17.0 million in the first nine months of 2023 decreased $2.2 million, or 11.7%, from $19.2 million in the first nine months of 2022. This decrease included a $1.9 million decrease in MGI Grain revenues and $0.3 million decrease in Golden Ridge revenues.

 

However, our gross loss of $0.5 million in the first nine months of 2023 improved 47.9% from a gross loss of $1,0 million in the first nine months of 2022 about equally at both MGI Grain and Golden Ridge gross due to the elimination of certain operating inefficiencies.

 

SG&A expenses of $4.3 million in the first nine months of 2023 increased $0.3 million or 8.3% compared to $4.0 million in the first nine months 2022 due to increased legal and consulting costs incurred as we continue to explore all our strategic alternatives.

 

Loss from continuing operations before other income (expense) was $4.8 million in the first nine months of 2023, compared to $5.0 million for the same period of 2022 because of, as noted above, the impact of our improved gross margin offset by increased SG&A expenses.

 

Other income, net, increased $0.2 million from the nine months of 2023 compared to same period of 2022 mainly due to the favorable impact of a $0.3 million restitution payment from a former employee, which had been ordered by a federal court in 2012.

 

As a result of the above our loss from continuing operations in the first nine months of 2023 was $5.1 million, or $0.77 per share, compared to $5.4 million, or $1.03 per share, in the first nine months of 2022.

 

17

 

Liquidity, Going Concern and Capital Resources

 

We had $0.5 million in cash and equivalents as of September 30, 2023, a decline of $0.6 million from December 31, 2022, after considering repayments of $3.0 million on our factoring, line of credit, long term debt and finance lease liabilities. In our continuing operations, during the first nine months of 2023, we used $0.5 million of cash to fund operations and $1.1 million to fund capital expenditures. This was offset by $0.5 million of net cash provided by the operation and disposition of our SRB Business in the first nine months of 2023.

 

On December 1, 2023, an entity owned by Cable Car Capital LLC, Funicular Funds, LP (Funicular), purchased $0.4 million of shares of common stock of the Company and lent the Company $4.0 million, less an original issue discount of $0.4 million.

 

Related to this financing, Funicular was also granted warrants to purchase up to 5.0 million shares of common stock of the Company.  If Funicular exercised all its warrants, it would own 49.8% of the Company.  The Company also exchanged existing warrants with other investors to purchase an aggregate 2.2 million shares of common stock of the Company for an aggregate of approximately 0.6 million shares of common stock of the Company and new warrants to purchase 1.2 million shares of common stock of the Company. 

 

With the proceeds of this financing, the Company repaid its $1.5 million mortgage note (see Note 9) and will use the remaining balance to fund its current and future general working capital and operating, investing and financing cash flow needs.

 

The Company believes this financing will be adequate to fund the Company’s planned operations over the next twelve months from the issuance of these Unaudited Condensed Consolidated Financial Statements.

 

The Company also believes additional cash can be secured through other debt or structured equity financing, if necessary. However, there can be no assurance that equity or debt financing will be available to the Company should it need it or, if available, that the terms will be satisfactory to the Company and not dilutive to existing shareholders. The Company’s failure to raise capital as and when needed could have significant negative consequences for its business, financial condition, and results of consolidated operations.

 

On March 30, 2020, we entered into a sales agreement with respect to an at-the-market (ATM) offering program, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $6.0 million, which we currently have $2.8 million remaining. Under the terms of the securities purchase agreement related to a September 2021 offering, we are prohibited from entering into an agreement to effect any at-the-market issuance until September 13, 2023. Under the terms of the securities purchase agreement related to the October 2022 offerings, we are generally prohibited from entering into a variable rate transaction, as defined in the agreement, until October 20, 2023.

 

Critical Accounting Estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses and disclosures on the date of the financial statements. On an ongoing basis, we evaluate the estimates, including, but not limited to, those related to revenue recognition, inventory valuation, and long-lived asset impairment. We use authoritative pronouncements, historical experience and other assumptions as the basis for making judgments. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

 

See Note 4 in the Notes to Unaudited Condensed Consolidated Financial Statements for further discussion.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

We are a smaller reporting company as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the Exchange Act) and are not required to provide the information otherwise required by this item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required financial disclosures. As of September 30, 2023, there have been no significant changes to our critical accounting policies and related estimates previously disclosed in our 2022 Annual Report on Form 10-K.

 

18

 

We evaluated, with the participation of our executive chairman, and interim chief financial officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our executive chairman and interim chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

 

Changes in Internal Control over Financial Reporting

 

During the most recently completed fiscal quarter, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are involved in or subject to, or may become involved in or subject to, routine litigation, claims, disputes, proceedings and investigations in the ordinary course of business. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position, results of operations or cash flows. We record accruals for contingencies when it is probable that liability will be incurred, and the amount of loss can be reasonably estimated.

 

Item 1A. Risk Factors

 

In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and the factor discussed in Part II, “Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2023, which could materially affect our business, financial condition, liquidity or future results. The risks described in our Annual Report on Form 10-K, Quarterly Report on Form 10-Q and below are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, liquidity or future results.

 

Our common stock was delisted from Nasdaq, which may adversely affect our stock price and the liquidity of our stock and could impact our ability to obtain financing could be impaired.

 

On October 30, 2023, we received a Staff Delisting Determination (the Staff Determination) from the Nasdaq Listing Qualifications Department (the Staff). The Staff Determination was issued as a result of the Company failing to comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing as set forth in Nasdaq Listing Rule 5550(b) (the Listing Requirement). On the basis of the Staff’s review and materials submitted by the Company to Nasdaq on October 9, 2023 and October 23, 2023, the Staff determined that the Company did not provide a definitive plan evidencing its ability to achieve near term compliance with the Listing Requirement or sustain such compliance over an extended period of time. Accordingly, trading in the Company’s common stock was suspended at the open of business on November 8, 2023 removing the Company’s securities from listing and registration on Nasdaq. We have transferred the quotation of our common stock to the over-the-counter markets operated by OTC Markets Group Inc. The shares of the Company’s common stock are currently trading under the symbol of “RIBT” on OTC Pink Market.

 

The delisting of our common stock from Nasdaq may negatively impact our Company and holders of our common stock, including the willingness of investors to hold our common stock because of the resulting decreased price, liquidity and trading of our common stock, limited availability of price quotations and reduced news and analyst coverage. There can be no guarantee that a broker will continue to make a market in our common stock and that trading will continue on the OTC Pink Market. The delisting from Nasdaq may further adversely impact the perception of our financial condition, cause reputational harm with investors, our employees and business partners, and limit our access to debt and equity financing.

 


 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

During the quarter ended September 30, 2023, we issued the securities described below without registration under the Securities Act of 1933, as amended (the Securities Act). The description below does not include issuances that we disclosed previously on Current Reports on Form 8-K.

 

19

 

Unless otherwise indicated below, the securities were issued pursuant to the private placement exemption provided by Section 4(a)(2) of the Securities Act. All issuances below were made without any public solicitation, to a limited number of sophisticated persons and were acquired for investment purposes only.

 

On September 30, 2023, we issued 600 shares of common stock to a service provider, that is not a natural person, as compensation for service provided. These shares were valued at an aggregate of $444.

 

Item 3. Defaults upon Senior Securities

 

None

 

Item 4. Mine Safety Disclosures

 

None

 

Item 5. Other Information

 

None

 

Item 6. Exhibits

 

20

 

The following exhibits are attached hereto and filed herewith:

 

       

Incorporated by Reference

   

Exhibit

Number

 

Exhibit Description

 

Form

 

File No.

 

Exhibit

Number

 

Filing / Effective

Date

 

Filed

Here-with

3.1

 

Certificate of Determination of Series H Junior Participating Preferred Stock

 

 

 

 

 

 

 

 

 

X

3.2   Amendment to Bylaws, effective August 30, 2023   8-K   001-36245   3.1   August 30, 2023    

4.1

 

Tax Benefits Preservation Plan, dated as of July 6, 2023, with American Stock Transfer & Trust Company, LLC, as Rights Agent.

 

8-K

 

001-36245

 

4.1

 

July 6, 2023

   
10.1   Agreement for Purchase And Sale with Republic Business Credit, LLC (incorporated by reference to Exhibit 10.1 to the Companys Form 8-K filed on November 1, 2019).    8-K   001-36245   10.1   September 14, 2023    
16.1   Letter from RSM US LLP to the Securities and Exchange Commission, dated August 23, 2023.   8-K   001-36245   16.1   August 23, 2023    

31.1

 

Certification by Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

                 

X

31.2

 

Certification by Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

                 

X

32.1

 

Certification by Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

                 

X

101.INS (1)

 

Inline XBRL Instance Document

                 

X

101.SCH (1)

 

Inline XBRL Taxonomy Extension Schema Document

                 

X

101.CAL (1)

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

                 

X

101.DEF (1)

 

Inline XBRL Taxonomy Extension Calculation Definition Linkbase Document

                 

X

101.LAB (1)

 

Inline XBRL Taxonomy Extension Calculation Label Linkbase Document

                 

X

101.PRE (1)

 

Inline XBRL Taxonomy Extension Calculation Presentation Linkbase Document

                 

X

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

                   

 

 

(1)

XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

21

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated:  December 20, 2023

   
     
 

/s/ Eric Tompkins

 
 

Eric Tompkins

 

Director and Executive Chairman

 

 

/s/ William J. Keneally

 
 

William J. Keneally

 

Interim Chief Financial Officer

 

22